Fructose‑1,6‑bisphosphatase‑1 decrease may promote carcinogenesis and chemoresistance in cervical cancer

Li,Haoran; Li,Mengjiao; Pang,Yangyang; Liu,Fei; Sheng,Dong; Cheng,Xi

doi:10.3892/mmr.2017.7665

Fructose‑1,6‑bisphosphatase‑1 decrease may promote carcinogenesis and chemoresistance in cervical cancer

Authors:
- Haoran Li
- Mengjiao Li
- Yangyang Pang
- Fei Liu
- Dong Sheng
- Xi Cheng
View Affiliations

Affiliations: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, Institute of Urology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu 730000, P.R. China , Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/mmr.2017.7665
Pages: 8563-8571

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fructose-1,6-bisphosphatase-1 (FBP1), a gluconeogenesis rate-limiting enzyme expressed in various tissues, is important in the carcinogenesis of various cancers. To evaluate the association of FBP1 expression and carcinogenesis and chemoresistance in cervical cancer, the present study analyzed 140 patients of squamous cell carcinoma of cervical cancer (CSCC) who had adjuvant concurrent chemoradiation therapy following radical surgery. By detecting FBP1 protein expression in paraffin‑embedded tumor tissues through immunohistochemistry, it was observed that 50% of the cases had a low expression of FBP1, which was associated with a shorter overall survival time (P=0.011). In addition, FBP1 mRNA level was downregulated in tumor tissues, compared with cervical normal tissues. Among the tumor‑associated prognostic factors, loss of FBP1 expression (χ2‑test, P=0.025) was significantly associated with the tumor recurrence and greater tumor stage of cervical cancer patients (2‑test, P<0.0001). In 3‑(4,5)‑dimethylthiahiazo(‑z‑y1)-3,5-diphenytetrazoliumromide (MTT) assay of primary tumor cells, the median in vitro inhibition rate of cisplatin, carboplatin, nedaplatin, and oxaliplatin was 62, 47, 58 and 52%, respectively. Although there was no significant association between FBP1 expression and in vitro tumor inhibition rates of primary tumor cells, overexpression of FBP1 markedly suppressed carcinogenesis and restored the chemosensitivity to cisplatin in cervical cancer cell lines of HeLa and CaSki. Overall, decreased levels of FBP1 may be used as a predictor for poor prognosis of cervical cancer patients, however the mechanism requires further investigation.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, et al: A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The snap-02 Italian collaborative study. Ann Oncol. 20:660–665. 2009. View Article : Google Scholar : PubMed/NCBI
3	Katanyoo K, Tangjitgamol S, Chongthanakorn M, Tantivatana T, Manusirivithaya S, Rongsriyam K and Cholpaisal A: Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol. 123:571–576. 2011. View Article : Google Scholar : PubMed/NCBI
4	Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M, et al: Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 16:1515–1524. 2015. View Article : Google Scholar : PubMed/NCBI
5	Monk BJ and Tewari KS: Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 32:2687–2690. 2014. View Article : Google Scholar : PubMed/NCBI
6	Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tillmann H and Eschrich K: Isolation and characterization of an allelic cDNA for human muscle fructose-1,6-bisphosphatase. Gene. 212:295–304. 1998. View Article : Google Scholar : PubMed/NCBI
8	Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, Yu J, Chan FK, Sung JJ and Jin HC: Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis. Oncogene. 29:442–450. 2010. View Article : Google Scholar : PubMed/NCBI
9	Chen M, Zhang J, Li N, Qian Z, Zhu M, Li Q, Zheng J, Wang X and Shi G: Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One. 6:e255642011. View Article : Google Scholar : PubMed/NCBI
10	Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC: Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
11	Bigl M, Jandrig B, Horn LC and Eschrich K: Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer. Biochem Biophys Res Commun. 377:720–724. 2008. View Article : Google Scholar : PubMed/NCBI
12	Heiden MG Vander, Cantley LC and Thompson CB: Understanding the warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
13	DeBerardinis RJ and Thompson CB: Cellular metabolism and disease: What do metabolic outliers teach us? Cell. 148:1132–1144. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cheng X, Cai SM, Li ZT, Wu XH, Ding YQ, Wang XE and Zang RY: Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases. Int J Gynecol Cancer. 18:779–784. 2008. View Article : Google Scholar : PubMed/NCBI
15	Shi TY, Yang G, Tu XY, Yang JM, Qian J, Wu XH, Zhou XY, Cheng X and Wei Q: RAD52 variants predict platinum resistance and prognosis of cervical cancer. PLoS One. 7:e504612012. View Article : Google Scholar : PubMed/NCBI
16	Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J and Kavanagh JJ: Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 121:323–327. 2011. View Article : Google Scholar : PubMed/NCBI
17	Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 49:6449–6465. 1989.PubMed/NCBI
18	Fella K, Glückmann M, Hellmann J, Karas M, Kramer PJ and Kröger M: Use of two-dimensional gel electrophoresis in predictive toxicology: Identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics. 5:1914–1927. 2005. View Article : Google Scholar : PubMed/NCBI
19	Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, et al: Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Res. 76:3265–3276. 2016. View Article : Google Scholar : PubMed/NCBI
20	Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA and Jones PA: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
21	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
22	Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al: Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 23:316–331. 2013. View Article : Google Scholar : PubMed/NCBI
23	Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet. 358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
24	Zuliani AC, Esteves SC, Teixeira LC, Teixeira JC, de Souza GA and Sarian LO: Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: A randomized controlled trial. J Clin Oncol. 32:542–547. 2014. View Article : Google Scholar : PubMed/NCBI
25	Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T and Yoshikawa H: Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized phase III trial JCOG0505. J Clin Oncol. 33:2129–2135. 2015. View Article : Google Scholar : PubMed/NCBI
26	Mabuchi S, Isohashi F, Yokoi T, Takemura M, Yoshino K, Shiki Y, Ito K, Enomoto T, Ogawa K and Kimura T: A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol. 141:240–246. 2016. View Article : Google Scholar : PubMed/NCBI
27	Dunst J and Haensgen G: Simultaneous radiochemotherapy in cervical cancer: Recommendations for chemotherapy. Strahlenther Onkol. 177:635–640. 2001. View Article : Google Scholar : PubMed/NCBI
28	Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H, Hijiya K, Aoyama A, et al: Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 6:288–297. 2017. View Article : Google Scholar : PubMed/NCBI
29	Song K, Li M, Xu X, Xuan Li, Huang G and Liu Q: Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia. Oncol Lett. 12:334–342. 2016.PubMed/NCBI